Conventional chemotherapy has little activity in this disease, but case reports are available on the activity of mammalian target of rapamycin inhibitors (e.g. sirolimus and temsirolimus). Pharmacokinetic assays of sirolimus are available as this drug has a precise therapeutic window and blood levels might be influenced by CYP3A4 polymorphisms and drug interactions. We report on a case of a patient with metastatic, progressive PEComa who started sirolimus at a dose of 5 mg/day with evidence of grade (G) 3 mucositis, G2 thrombocytopenia, and G1 leucopenia 10 days after the treatment started, in absence of concomitant medications or prohibited food assumption. Elevated sirolimus blood levels were detected (156.8 ng/ml). Sirolimus was stopped, and toxicity resolved in 5 weeks. Computed tomography scan 2 months after the treatment started showed a partial response (RECIST). After toxicity resolution, the patient restarted sirolimus at a dose of 1 mg/day, with blood levels in the range of 10-20 ng/ml. Tumor response was confirmed and maintained, and the patient is still under treatment 18 months later, with no additional adverse effects. Genetic analysis of five selected polymorphisms (rs2740574, rs776746, rs1128503, rs2032582, and rs1045642) in drug metabolism enzymes and transporters did not provide a clear explanation of the observed unusual pharmacokinetic. This case confirms the activity of mammalian target of rapamycin inhibitors in PEComa and strengthens the importance of pharmacokinetic drug blood levels monitoring in patients treated with sirolimus. In our patient, after dose adjustment, sirolimus could be restarted with a prolonged clinical benefit and no additional toxicity. Anti-Cancer Drugs 29:589-595 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Perivascular epithelioid cell tumors (PEComas) represent a family of mesenchymal tumors, often misdiagnosed in the past as epithelioid smooth muscle tumors or melanoma [1] . This category comprises, among others, angiomyolipoma of the kidney, clear cell ('sugar') tumor of the lung, lymphangioleiomyomatosis of the lung, and less well-characterized PEComas of a variety of other anatomic origins, for which the term 'perivascular epithelioid cell tumor not otherwise specified' has been proposed [2, 3] . All these entities are characterized by the presence of the 'perivascular epithelioid cell' identified for the first time in the 1990s by Bonetti et al. [4] . The perivascular epithelioid cell is characterized by the co-expression of myogenic (smooth muscle antigen and/or desmin) and melanocytic markers (HMB-45, melan-A, and MITF). HMB-45 and smooth muscle actin represent the most sensitive markers [5] . In~10% of cases, nuclear expression of TFE3 is observed that is most often related to TFE3 gene rearrangement.
PEComas are endowed with a variable clinical behavior, ranging from benign or indolent cases to malignant diseases with metastatic potential. No standardized classification of risk has been established. However, the presence of necrosis, mitotic activity, and pleomorphism is commonly associated with an aggressive behavior [6] .
A proportion of PEComas are associated with tuberous sclerosis complex (TSC), an autosomal dominant genetic disease owing to losses of TSC1 (27%) on chromosome 9q34 or TSC2 (73%) on chromosome 16p13.3. TSC 1 and TSC2 encode for hamartin and tuberin, respectively, both involved in the regulation of the Rheb/mTOR/ p70S6K pathway [7] . TSC1 and TSC2 work together as a heterodimer that inhibits the mTORC1 kinase, which drives the mammalian target of rapamycin (mTOR) metabolic signaling. The loss of TSC1 or TSC2 leads to a constitutive activation of mTOR pathway, fostering cell growth, proliferation, and angiogenesis [8] . TSC1/2 loss and mTOR hyperactivation have also been reported in non-TSC-related PEComas, by using as surrogate marker the immunohistochemical positivity of p70S6K [9] . The possible role of the mTOR pathway in PEComas as an oncogenic driver underlies the rationale for mTOR inhibition as a treatment option, which is today supported by recent studies and case series available in the literature [10] [11] [12] [13] [14] [15] [16] [17] .
It is well known that mTOR inhibitor blood levels can be widely variable. Sirolimus is metabolized by liver microsomes. Polymorphisms in CYP450 family genes or in transport proteins, such as ABCB1, together with the possible interactions with drugs metabolized by the same enzymatic pathway could explain such heterogeneity [18] [19] [20] [21] [22] . Patient age, sex, and liver function may also affect the pharmacokinetics of the drug. Therefore, pharmacokinetic assessment is advisable at baseline and during treatment with sirolimus [23] .
Differently from recommendations regarding the administration of these drugs in patients with a kidney transplantation, the dosage is usually kept steady in patients with cancer. Generally, monitoring of drug blood levels is not performed, too.
Herein, we report a case of a man affected by a progressive, metastatic renal PEComa who was treated with sirolimus and achieving a prolonged disease response. Severe toxicity was observed after few days of treatment, in correlation with the concomitance of very elevated sirolimus blood levels.
Case presentation
A 61-year-old man, asymptomatic, in good general conditions, with no relevant medical history, came to our attention at Fondazione IRCCS Istituto Nazionale Tumori in February 2016. He presented with a multinodular, bilateral, pulmonary relapse of a renal non-TSCrelated PEComa. The primary tumor was excised with a left nefrectomy in 2007. In 2014, he developed metastatic disease in the lung and was histologically assessed at the time of progression in February 2015. The diagnosis of PEComa was confirmed by morphology and by immunohistochemistry, showing neoplastic cells positive for both melanocytic (HMB-45) and smooth muscle (SMA, caldesmon) markers, focally positive for S-100, and negative for desmin, myogenin, melan-A, MiTF, TFE3, and EMA ( Fig. 1 ).
Radiological restaging did not detect extrapulmonary disease. On the basis of the pathological diagnosis and the tumor extent, the patient was started on a first-line treatment with sirolimus in February 2016 ( Fig. 2a and b) . Sirolimus was administered orally at the daily dose of 5 mg, within a named use program. The patient was taught to take the drug in the morning, when fasting, at the same time. A blood level testing was planned after 15 days of treatment with sirolimus, to possibly modify the dose to keep the blood concentration within the therapeutic range (10-20 ng/ml). A new computed tomography (CT) scan to evaluate response was scheduled after 2 months of treatment.
After 10 days of treatment, the patient reported the onset of G3 oral mucositis (according to CTCAE 4.0) (Fig. 3) , which led to sirolimus discontinuation. Blood tests showed G1 leucopenia and G2 thrombocytopenia. Sirolimus blood level at 14 days from the treatment start was found to be significantly higher than the therapeutic range upper limit (156.8 ng/ml) after a dilution of 1 : 8. Quantitative determination of sirolimus was performed in the whole blood using chemiluminescent microparticle immunoassay technology (Abbott Diagnostics, Wiesbaden, Germany). The measurement range for this assay is 2-30 ng/ml. The sample resulting with a value greater than 30 ng/ml was diluted according to manufacturer's instructions.
The oral mucositis was managed in an outpatient setting, with regular flurbiprofen mouthwashes and application of vitamin E on mouth ulcers. Food intake was limited to liquid for~2 weeks. Subsequent pharmacological assays showed a complete drug washout. Complete remission of all toxicities was achieved as soon as sirolimus level dropped under 2 ng/ml, 5 weeks after suspension. To clarify the causes of this toxicity, possible drug-drug interactions and/or incorrect drug intake were investigated and excluded.
At 2 months from sirolimus start (April 2016), 6 weeks after treatment interruption, and after only 10 days of actual drug assumption, CT scan showed a RECIST partial response (right nodule halved from 18 to 9 mm and the left nodule reduced from 9 to 6 mm) ( Fig. 2c  and d) . In addition, a genetic study investigating polymorphisms of liver cytochrome P450 family enzymes and ABCB1 transporter was performed. In detail, rs2740574 (CYP3A4*1B), rs776746 (CYP3A5*3), rs1128503 (ABCB1 1236C > T), rs2032582 (ABCB1 2677T > A), and rs1045642 (ABCB1 3435C > T) single nucleotide polymorphisms (SNPs) were genotyped by Sanger sequencing. The patient resulted to be homozygous T/T for rs2740574 and homozygous C/C for rs776746 in CYP3A4 and CYP3A5, respectively. He was homozygous for the wild-type allele at rs1128503 (G) and rs2032582 (C), whereas he was heterozygous (C/T) for rs1045642 polymorphism in ABCB1 (Table 1) .
Given the convincing response achieved in such a short time, sirolimus was restarted with a closed medical monitoring, at the dose of 1 mg daily. Sirolimus blood level was monitored through test at day 7, day 14, and subsequently once a month. After its reintroduction, sirolimus was well tolerated, regularly taken at the dose of 1 mg/day, without additional interruptions. Sirolimus was taken with a regular schedule, while fasting, and blood draw was always performed the following day, 18 hours after the last dose administered. His blood level was found to be in the range of 10-20 ng/ml and remained stable over time at the following controls. In October 2017, after 18 months from the treatment resumption, the patient was still receiving the same dose, with no relevant toxicities. Radiological response was maintained in the last CT scan, performed in September 2017 (Fig. 2e and f) .
Discussion
We report on a patient with metastatic PEComa treated with sirolimus, achieving a prolonged response. He developed severe toxicities associated with a highly abnormal blood drug level while receiving sirolimus at the conventionally used dose of 5 mg/day. With the reintroduction of sirolimus at a lower dose (1 mg/day), the disease response was maintained and the patient is still progression free 17 months later, with no relevant toxicity reported.
The evidence of the mTOR pathway up-regulation in PEComas provided the rationale for mTOR inhibitor testing in this rare disease. Current knowledge is based on limited retrospective experiences and case reports [10] [11] [12] [13] [14] [15] [16] . Benson et al. [17] published the largest series of patients with PEComa treated with mTOR inhibitors, showing the activity of these compounds in a proportion of patients. In available series, doses were variable, and no standard dose of sirolimus was established. Median administered dose was 4 mg daily, with schedules from 3 mg/day to 5 mg according to patient tolerability, or with a loading dose of 6 mg followed by a daily dose of 3 mg [10] [11] [12] [13] [14] [15] [16] [17] . Because of the rarity of the disease, no international trial has been carried out so far on mTOR inhibitors in PEComa, although a phase 2 study is ongoing in the USA. Sirolimus was originally introduced for the prophylaxis of organ rejection as immunosuppression therapy after renal transplantation. In this indication, the most widely used regimen is a 6-mg single oral loading dose, followed by individualized dosing, adjusted to ensure a maintenance of drug blood levels between 4 and 12 ng/ml on the basis of chromatographic methods [18] . Several assay methodologies have been used to measure the whole blood concentrations of sirolimus, among which chromatographic and immunoassay are the most common in routine clinical practice. The results obtained through different methodologies are not comparable; therefore, local assay should always be specified and adjustment to the targeted therapeutic range must be made accordingly. Moreover, to minimize variability, it is advisable to consistently take sirolimus at the same time of the day and either with or without food [19, 20] . Studies conducted in patients receiving renal grafts showed a remarkable pharmacokinetic variability in drug blood levels, linked to patient characteristics such as age, sex, and liver function, as well as to polymorphic variants of hepatic enzymes CYP3A4 and CYP3A5. Interaction with other concomitant medications metabolized by the same liver cytochromes, if any, can also play a role. The pharmacokinetic assessment of sirolimus blood levels is useful, with a therapeutic recommended window between 5 and 20 ng/ml in nononcologic indications, as most adverse events have been seen when drug blood levels exceed 15-20 ng/ml [18] [19] [20] .
The US Food and Drug Administration approved sirolimus to treat lymphangioleiomyomatosis, which belongs to the PEComa family. This was based on the results of a two-stage, randomized, and double-blind trial. The study included the assessment of blood levels of sirolimus at each visit to maintain sirolimus levels between 5 and 15 ng/ml in the active-treatment group, except in four cases in which levels were intentionally kept below therapeutic levels to control adverse effects. As anticancer drugs, sirolimus and other mTOR inhibitors are administered at a fixed starting dose, irrespective of individual characteristics and/or blood monitoring [21] .
Cytochromes P450 (CYP) is a family of enzymes involved in catalyzing the metabolism of numerous endogenous and exogenous molecules. Approximately 55 different CYP genes are present in the human genome. The most important and best-characterized CYPs are the members of the CYP3A4 subfamily, which seem to play a key role in the metabolism of most anticancer drugs. They are inducible enzymes; therefore, their activity is decreased Fig. 3 Mucosal toxicity. Mucosal toxicity treatment related to sirolimus, with oral mucositis on the tongue (a) and on the internal part of the inferior lip (b). PEComa: sirolimus activity and toxicity Raimondi et al. 593
or increased as a result of interactions with concomitant food and drugs acting as inhibitors or inducers [22, 23] . Sirolimus is extensively metabolized by the CYP3A subfamily, in particular CYP3A4 and CYP3A5, and partially through CYP2C8. Such multiple contribution is demonstrated by the observation that ketoconazole, a selective and potent CYP3A4 inhibitor, inhibits sirolimus metabolism by more than 90% in both pooled liver and intestinal microsomes. In this sense, the common CYP3A5*3 allele found in the gene encoding for CYP3A5 has been of great interest as a potential factor to explain the observed interindividual differences in pharmacokinetics and bioavailability of sirolimus [24] . This allele is due to single nucleotide variations that cause alternative splicing resulting in the absence of functional CYP3A5. Several studies have reported sirolimus exposure to be significantly higher in 'non-expresser' people, who are homozygous for the CYP3A5*3 allele. However, because of discrepancies across different studies, no consensus has been reached to date on the real influence of the CYP3A5 genotype on sirolimus pharmacokinetics and, thus, how to implement this information in the clinical practice [25, 26] .
Genetic polymorphisms of drug metabolizers and/or transporters could also somehow influence drug metabolism. Among them, ABCB1 or P-glycoprotein is a transmembrane protein-transporter that mediates the efflux of drug compounds through biological barriers. Thus, an identical dose regimen can result in widely different concentrations of the therapeutically active component [26, 27] .
To investigate the possible role of polymorphisms in genes involved in sirolimus metabolism in our patient, we analyzed five genetic variants in CYP3A4, CYP3A5, and ABCB1. In detail, our patient was homozygous for the wild-type allele at SNP rs2740574 (T) in CYP3A4 and homozygous for the variant allele at SNP rs776746 (C) in CYP3A5 (CYP3A5*3 allele). CYP3A5*3 allele has already been reported to correlate with a decreased clearance of sirolimus and a high blood concentration. This is consistent with what we observed in our patient, thus suggesting that his genotype might explain at least partially his response to sirolimus. However, no sufficiently strong evidence is available in literature, as results about the CYP3A5*3 allele are often controversial [28] . Regarding ABCB1, our patient was heterozygous for rs1045642 (C/T) polymorphism. Data on the role of this polymorphism are conflicting, with some reports [29] suggesting that T carriers have a sirolimus concentration/dose ratio higher than patients carrying the C allele, whereas others show no significant correlations with dose-normalized sirolimus concentration [26, 30, 31] . Alleles at rs1128503 (G) and rs2032582 (C) were found to be wild type, but none of these have been found to be associated with a variation in sirolimus metabolism [26, 30, 31] . In brief, only rs776746 and rs1045642 could explain the high concentration of drug in the blood of our patient. However, for both SNPs literature, more data are required to drive definitive conclusions. Finally, we cannot exclude the involvement of rs2740574 of CYP3A4 and of rs776746 of CYP3A5 in the modulation of sirolimus metabolism, but, as the alleles carried by our case at these two SNPs are very frequent in the Italian population, no definitive correlation can be established.
To better understand the role of genetics in determining the response to sirolimus, studies on a larger cohort of patients with a genome-wide approach are needed. However, our case underlies that therapeutic monitoring of drugs can be clinically useful to predict toxicity or efficacy of oral antineoplastic agents. Pazopanib is another example of an oral anticancer drug approved for the treatment of sarcoma in which pharmacokinetics is fundamental and conditions a remarkable interpatient and intrapatient variability. In a recent trial, it was underlined that its efficacy is linked to obtaining levels of at least 20 mg/l, and in ∼ 20% of patients, they are not reached with a potential undertreatment [32] . Pazopanib exposure is reduced by proton pump inhibitors whereas increased by food and drugs inhibitors of CYP3A4 such as ketoconazole; moreover, several biomarkers associated with higher or lower response could be identified.
Conclusion
This case report confirms the activity of sirolimus in advanced PEComa and underlies that blood drug assessment is relevant for both activity and toxicity management. Moreover, it shows how a patient-tailored approach, with treatment schedules personalized according to blood levels and clinical tolerability, is feasible and desirable. Further studies, involving a larger group of patients, are needed to clarify the role of pharmacokinetic testing and polymorphisms in drug metabolizers and/or transporters assessment in patients undergoing treatment with sirolimus.
